SAIPARENT
1 call
Concalls & earnings callsSai Parenterals Limited
Every summarised call, newest first. Latest is Q1 FY27, held 12 Aug 2026.
Latest quarter
Q1 FY27 snapshot
Open full brief →The quarter was about improved margins on a seasonally lower revenue base and the strategic reallocation of IPO funds to acquire majority stakes in two operating pharmaceutical assets, accelerating entry into complex injectables and R&D.
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Consolidated Total Revenue | ₹182 Cr | — | |
| Gross Profit Margin | 41.8% | 370 bps | |
| EBITDA Margin | 14.9% | 50 bps | |
| Profit After Tax Margin | 4.3% | — |
Latest guidance
- Full-year revenue target of Rs. 750 crores for FY27.
- EBITDA margin of around 17% for FY27.
- Revenue split of 45:55 between the first and second halves of the year.
- Australian facility physical completion targeted for January 2027, with TGA licensing inspection by March 2027 and Phase 1 manufacturing from April 2027.
- New injectable facility (Saicriti) completion extended only about a month to April 2027.
Said on the Q1 FY27 call.
Call history
- Q1 FY27Positive tone
The quarter was about improved margins on a seasonally lower revenue base and the strategic reallocation of IPO funds to acquire majority stakes in two operating pharmaceutical assets, accelerating entry into complex injectables and R&D.
- Consolidated Total Revenue
- ₹182 Cr
- Gross Profit Margin
- 41.8%370 bps